Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer

Orazio Caffo, Gaetano Facchini, Elisa Biasco, Francesco Ferraù, Franco Morelli, Maddalena Donini, Consuelo Buttigliero, Nicola Calvani, Annalisa Guida, Vincenzo Emanuele Chiuri, Umberto Basso, Claudia Mucciarini, Vincenza Conteduca, Sabrina Rossetti, Antonello Veccia, Francesca Maines, Stefania Kinspergher, Ugo De Giorgi

Research output: Contribution to journalArticle

Abstract

AIM: To evaluate activity of metronomic cyclophosphamide (mCTX) in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients.

PATIENTS & METHODS: We retrospectively evaluated a consecutive series of 74 mCRPC patients treated with at least one new agent after docetaxel failure, who received once daily oral mCTX treatment at a fixed dose of 50 mg.

RESULTS: The treatment was well tolerated. Sixteen percent of the patients experienced a major biochemical response. Median progression-free survival was 4.0 months, and median overall survival was 8.1 months.

CONCLUSIONS: In the modern context of mCRPC, mCTX may represent a valuable and inexpensive alternative to new agents, which have shown similar activity in heavily pretreated patients.

Original languageEnglish
JournalFuture Oncology
DOIs
Publication statusPublished - Mar 19 2019

Fingerprint Dive into the research topics of 'Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer'. Together they form a unique fingerprint.

  • Cite this

    Caffo, O., Facchini, G., Biasco, E., Ferraù, F., Morelli, F., Donini, M., Buttigliero, C., Calvani, N., Guida, A., Chiuri, V. E., Basso, U., Mucciarini, C., Conteduca, V., Rossetti, S., Veccia, A., Maines, F., Kinspergher, S., & De Giorgi, U. (2019). Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer. Future Oncology. https://doi.org/10.2217/fon-2018-0715